Skip to main navigation
Skip to search
Skip to main content
Research Profiles at Washington University School of Medicine Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Checkpoint immunotherapy in head and neck cancers
Paul Zolkind
, Ravindra Uppaluri
Department of Otolaryngology
Research output
:
Contribution to journal
›
Article
›
peer-review
34
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Checkpoint immunotherapy in head and neck cancers'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Head-and-neck Cancer
100%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
100%
Checkpoint Immunotherapy
100%
Clinical Trials
40%
Checkpoint Inhibitors
40%
Response Rate
20%
Monoclonal Antibody
20%
Improved Outcomes
20%
Cancer Cells
20%
Head-and-neck
20%
FDA-approved Drugs
20%
Immune System
20%
Durable Response
20%
Antigen Targeting
20%
Novel Combinations
20%
Progressive Disease
20%
Good Target
20%
Combination Therapy
20%
Immune Escape
20%
Immunosurveillance
20%
Immune Monitoring
20%
Checkpoint Therapy
20%
Standard-of-care Chemotherapies
20%
Mutation Burden
20%
Cisplatin Resistance
20%
PD-1/PD-L1 Axis
20%
Medicine and Dentistry
Immunotherapy
100%
Head and Neck Squamous Cell Carcinoma
100%
Head and Neck Cancer
100%
Biological Marker
66%
Clinical Trial
66%
Cancer Cell
33%
Combination Therapy
33%
Neck
33%
Monoclonal Antibody
33%
Cisplatin
33%
Programmed Death-Ligand 1
33%
Progressive Disease
33%
Immune System
33%
Immunity
33%
Immune Evasion
33%
Immunosurveillance
33%
Pharmacology, Toxicology and Pharmaceutical Science
Head and Neck Cancer
100%
Immunotherapy
100%
Head and Neck Squamous Cell Carcinoma
100%
Clinical Trial
66%
Biological Marker
66%
Combination Therapy
33%
Malignant Neoplasm
33%
Chemotherapy
33%
Cisplatin
33%
Monoclonal Antibody
33%
Diseases
33%
Biochemistry, Genetics and Molecular Biology
Clinical Trial
100%
Immunity
100%
Cancer Cell
50%
Monoclonal Antibody
50%
Immune Evasion
50%
Cisplatin
50%
PD-L1
50%
Immunosurveillance
50%
Immunology and Microbiology
Immunotherapy
100%
Neck
100%
Squamous Cell
50%
Monoclonal Antibody
16%
Cancer Cell
16%
Immune Evasion
16%
Immunity
16%
Programmed Death-Ligand 1
16%
Immunosurveillance
16%
Immune System
16%